Quick Answer
Biofrontera Inc. reported Revenue (ASC 606) of $41.70 million for fiscal year 2025.
Biofrontera Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $41.70M | +11.7% |
| 2024 | $37.32M | +9.5% |
| 2023 | $34.07M | +18.8% |
| 2022 | $28.67M | +19.0% |
| 2021 | $24.10M | +27.9% |
| 2020 | $18.85M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.99M | -22.5% | -22.6% |
| June 30, 2025 | $9.03M | +15.2% | +5.1% |
| March 31, 2025 | $8.59M | +8.5% | -4.7% |
| September 30, 2024 | $9.01M | +1.3% | +15.0% |
| June 30, 2024 | $7.84M | +34.0% | -0.9% |
| March 31, 2024 | $7.91M | -9.4% | -11.1% |
| September 30, 2023 | $8.90M | +105.8% | +52.1% |
| June 30, 2023 | $5.85M | +31.2% | -33.0% |
- Biofrontera Inc. showed an increase of +11.7% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2020–2025 period, Biofrontera Inc.’s revenue (asc 606) has grown by 121.3% (from $18.85 million to $41.70 million).
- The most recent figure is from Biofrontera Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: